The first patient has started Redwood Pharma’s RP501 treatment for dry eye
May 5, 2022 2:00 pm(Stockholm, Sweden, May 5, 2022) Redwood Pharma AB (publ) today announces that the first patient has been included in the company’s... View Article
(Stockholm, Sweden, May 5, 2022) Redwood Pharma AB (publ) today announces that the first patient has been included in the company’s... View Article
(Stockholm, 5 maj 2022) Redwood Pharma AB (publ) meddelar idag att den första patienten har inkluderats i bolagets kliniska prövning av RP501... View Article
Redwood Pharma will participate in the BioStock Life Science Summit in Lund and in Stockholm. CEO Martin Vidaeus will update... View Article
Redwood Pharma kommer att delta på BioStock Life Science Summit i Lund och i Stockholm. VD Martin Vidaeus kommer att uppdatera... View Article
The Association of Researchers in Vision and Ophthalmology will hold their annual meeting in Denver, Colorado (USA) between May 1-4,... View Article
Redwood Pharma AB (publ) meddelar idag att årsredovisningen för 2021 har offentliggjorts och finns tillgänglig på bolagets hemsida www.redwoodpharma.se/investerare/rapporter/. För... View Article
Aktieägarna i Redwood Pharma AB (publ), org.nr 556885–1280, kallas härmed till årsstämma tisdagen den 10 maj 2022 kl. 13.30 på Clarion... View Article
Redwood Pharma has received approval from the Austrian Federal Office for Safety in Health Care (BASG) to initiate the clinical trial... View Article
Redwood Pharma har erhållit godkännande från den österrikiska läkemedelsmyndigheten (Austrian Federal Office for Safety in Health Care, BASG) att inleda den... View Article